Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma

Wang, Nan; Lv, Yinzhang; Xu, Anhui; Huang, Yan-Rong; Peng, Ling; Li, Jiarui

doi:10.7314/apjcp.2014.15.2.647

Cited by 13 publications

(6 citation statements)

References 23 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its use, however, is limited by sometimes severe organ toxicity, especially neuro-and nephrotoxicity. Carboplatin shows a favorable spectrum of toxicity, with reversible myelosuppression being the dose-limiting toxicity (Deng et al, 2013;Huang et al, 2013;Peng et al, 2014;Wang et al, 2014;Wu et al, 2014;Zhao et al, 2014). Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Sun¹,

Lou²,

Sui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Lobaplatin, one of the third -generation platinum compounds, has shown encouraging anticancer activity in a variety of tumor types. However, the efficacy of lobaplatin in ovarian cancer has not been systemically evaluated. In this study, lobaplatin as a single agent and in combination with taxanes was investigated in -vitro and in an in vitro model of ovarian carcinoma. Using the sulforhodamine B (SRB) assay, the cytotoxic effects of lobaplatin alone and in combination with taxanes were compared with cisplatin and carboplatin in seven ovarian cancer cell lines. In addition, in -vitro antitumor activities were evaluated with cisplatin -sensitive and cisplatin -resistant human ovarian cancer xenografts in nude mice. The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with IC 50 values from 0.9 to 13.8 µmol/L in a variety of ovarian cancer cells. The combination of lobaplatin with docetaxel yielded enhanced cytotoxic activity in vitro. In addition, in platinum -sensitive ovarian cancer xenografts, lobaplatin alone showed similar antitumor activity to cisplatin and carboplatin. Furthermore, lobaplatin alone or in combination with docetaxel exhibited significant activity in platinum -resistant ovarian cancer xenografts. These results indicate that the use of lobaplatin alone or in combination with docetaxel might be a rational and novel therapeutic strategy for ovarian cancer. Further clinical development of lobaplatin is clearly warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Sun¹,

Lou²,

Sui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Another study of human non-small-cell lung cancer reported that the combination of lobaplatin with paclitaxel shows enhanced activity compared with cisplatin combined with paclitaxel 17 . Lobaplatin has also been shown to exhibit therapeutic efficacy in the treatment of hepatic cancer 18 , 19 , with a total effective rate of 67.6%.…”

Section: Introductionmentioning

confidence: 99%

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Tang

et al. 2018

Nat Commun

View full text Add to dashboard Cite

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

show abstract

“…The lower toxicity of LBP has been demonstrated in breast cancer ( 12 ), lung cancer ( 13 ), oesophageal carcinoma ( 14 ), and hepatic cancer ( 15 ). Patients with ESCC after surgery usually have worse PSs than those with other types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma

et al. 2021

View full text Add to dashboard Cite

ObjectivesLobaplatin (LBP), a third-generation cisplatin derivative has shown promising activity and few side effects in oesophageal squamous cell carcinoma (ESCC) in previous reports. We compared LBP plus docetaxel with cisplatin plus docetaxel as adjuvant chemotherapy in ESCC patients to determine the effects on overall survival (OS) and toxicity.MethodsA multicentre retrospective study was performed using propensity score matching (PSM) with the Medicine-LinkDoc database. Patients diagnosed with stage II-III ESCC treated with adjuvant chemotherapy (cisplatin plus docetaxel or LBP plus docetaxel) between January 2013 and December 2016 were selected from 6 centres in China.ResultsThere were 733 eligible ESCC patients. After PSM (1:1 ratio), 458 patients remained. The 5-year OS rates of the cisplatin and LBP groups were 25.9% and 23.6%, respectively (P=0.457). Leukopenia (grade III-IV/I-II/0: 2.62%/34.5%/59.39% versus 5.24%/43.23%/45.85%; P=0.0176), neutropenia (grade III-IV/I-II/0: 6.55%/37.56%/51.09% versus 4.37%/53.28%/36.34%; P=0.0015), nephrotoxicity (grade I-II/0: 13.97%/76.86% versus 26.64%/65.94%; P<0.001) and gastrointestinal symptoms (grade III-IV/I-II/0: 2.18%/54.59%/32.31% versus 6.55%/65.07%/20.88%; P=0.0011) were more frequent in the cisplatin group.ConclusionsCompared with cisplatin plus docetaxel, LBP plus docetaxel provided the same survival benefits but lower side effects of myelosuppression and gastrointestinal symptoms. LBP plus docetaxel might be a choice for adjuvant chemotherapy in ESCC.Clinical Trial RegistrationLobaplatin or Cisplatin in Adjuvant Chemotherapy for Oesophageal Carcinoma, identifier NCT03413436.

show abstract

Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma

Cited by 13 publications

References 23 publications

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma

Contact Info

Product

Resources

About